MedTrace Logo

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways

NCT01666613 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2012-12-19

No results posted yet for this study

Summary

The purpose of this study is to look at drug levels of AZD8683 in blood when the drug is administered in different ways - orally, intravenously or inhaled (with two different devices), to healthy subjects

Conditions

  • Healthy

Interventions

DRUG

AZD8683

Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683

DRUG

AZD8683

Solution to be administered orally Total dose of 950 µg AZD8683

DRUG

AZD8683

Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683

DRUG

AZD8683

Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683

Sponsors & Collaborators

Principal Investigators

  • Carin Jorup, MD · AstraZeneca R&D, Molndal Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-03-31
Completion
2013-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01666613 on ClinicalTrials.gov